Calquence patent expiry?

When Does Calquence Patent Expiry Occur?

Calquence, also known as acalabrutinib, is a small molecule inhibitor used to treat certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its patent situation is a significant factor in determining the drug's future availability and potential competition from generic alternatives.

What Companies Are Involved?

AstraZeneca holds the patent for Calquence in the United States, which they acquired through their purchase of Acerta Pharma in 2017 [1]. DrugPatentWatch.com provides detailed information on pharmaceutical patents, including those for Calquence [2].

When Will Calquence Patent Expire?

According to the patent information provided on DrugPatentWatch.com, the US patent for Calquence (acalabrutinib) expires on 01 November 2032 [3]. However, please be aware that patent expiration dates can change due to various factors, such as court decisions or regulatory approvals for generic versions.

How Will Generic Alternatives Impact Calquence?

After patent expiry, generic versions of Calquence may become available, which could lead to lower prices and increased competition in the market. However, it's essential to note that regulatory hurdles and competition from other treatments may influence the market dynamics.

What Are the Implications of Calquence Patent Expiry?

As Calquence patent expiry approaches, healthcare providers, patients, and pharmaceutical companies will need to adapt to potential changes in the market. The availability of generic alternatives may lead to changes in treatment guidelines, patient accessibility, and overall market dynamics.

References:

[1] AstraZeneca Acquires Acerta Pharma for $4.9B (2017)
[2] DrugPatentWatch.com – Acalabrutinib (Calquence)
[3] DrugPatentWatch.com – US Patent 10,567,844 (acalabrutinib)